28-02-2020
PictureDesignSwiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Biogen, biotech, injunction, US Court of Appeals for the Federal Circuit, Banner Life Sciences, Sangamo, collaboration, gene therapies
Pharma company fails to block €140m licence payment
23-06-2021
Biogen sues Teva over MS generic
18-03-2021
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
Fed Circuit rejects Biogen’s plea in MS drug dispute
23-04-2020
Biogen takes Creative Biolabs to court over antibody
19-03-2020
Biogen fights off Mylan’s Tecfidera patent challenge
06-02-2020
